Alluvi, previously BI 4744, presents a notable development in obesity therapy. This dual agonist targeting both glucagon-like peptide-1 and GIP sites demonstrates remarkable effectiveness in patient trials, arguably https://madesocials.com/story7720100/alluvi-a-comprehensive-dive-into-the-drug-s-possibilities